Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report
- 7 January 2022
- journal article
- conference paper
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (1) , 193-196
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literatureJournal for ImmunoTherapy of Cancer, 2019
- Checkpoint Inhibitor use in Two Heart Transplant Patients with Metastatic Melanoma and Review of High-Risk PopulationsMelanoma Management, 2018
- Acute interstitial nephritis related to immune checkpoint inhibitorsBritish Journal of Cancer, 2016
- Fulminant Myocarditis with Combination Immune Checkpoint BlockadeNew England Journal of Medicine, 2016
- Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case reportCancer Immunology, Immunotherapy, 2016
- Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of RejectionAmerican Journal of Transplantation, 2016
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1New England Journal of Medicine, 2016
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Essential Role of PDL1 Expression on Nonhematopoietic Donor Cells in Acquired Tolerance to Vascularized Cardiac AllograftsAmerican Journal of Transplantation, 2011
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationJournal of Experimental Medicine, 2000